search icon
  • Print
  • ShareThis
  • Text Size

In order to contribute to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.


Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.

RSS Feed Print Category View
J&J, Gilead combo drug therapy clears hep C in 100% of Phase IIa cohort
Posted: Monday, March 4, 2013 1:00 PM
Joined: 2/20/2013
Posts: 40

"Medivir has posted a stellar snapshot of interim data from its Phase IIa study of a combo hepatitis C treatment that adds Gilead's hot property--GS-7977--with the Swedish biotech's simeprevir (TMC435), which is partnered with Johnson & Johnson.

The combo therapy cleared the virus in 100% of the 80 genotype 1 patients divvied into four treatment groups. All of the patients were "null-responder" hepatitis C patients with mild to moderate fibrosis. And the clear rate was the same for patients receiving 12 weeks and 24 weeks of therapy, with or without ribavirin. There were no reported incidents of serious adverse events."

For more information, please visit:


| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site